One Health Seminar: One Health in a Changing World: From Guelph to Global Pandemic Preparedness

Jonathan Heeney, Professor at the University of Cambridge, is CSO and founder of DIOSynVax; “Digitally Immune Optimised Synthetic Vaccines”, a clinical stage Biotech based in Cambridge UK. DIOSynVax’s Computational Vaccine antigen technology leverages AI to design broadly protective vaccine antigen payloads to protect from high consequence diseases of humans and animals. The company has advanced vaccine candidates for seasonal, universal and pre-pandemic (H5Nx, H1N1, H7N2, etc) Influenza, pan-Beta Coronaviruses and a Mpox vaccine carrying broad Filovirus and Arenavirus payloads that protects from Marburg, Ebola Sudan, and Lassa virus challenges in animal models. Jonathan also heads The Laboratory of Viral Zoonotics at the University of Cambridge, a team of One Health researchers that studies the immune correlates of protection from zoonotic viral diseases that threaten humans. Translationally this information is utilized for the rational design of novel vaccines for the prevention of diseases caused by emerging and re-emerging viral pathogens.